Latest Issue

Contribution of Heparinemia in the Monitoring of Anticoagulant Treatments about 10 Cases and Review of the Literature

OukkasS, allaliA, yahyaouiH, aitameurM, chakour M, Morocco

(HNF) and low molecular weight heparins, used for biological monitoring of heparin-like anticoagulant therapy. This work aims to show the quality of heparin management thanks to the biological monitoring by anti-Xa activity in 10 cases. The average age of our cases was 58.9 years with a frequency peak between 55 and 57 years (40%) and a clear male predominance. The most common clinical entity was the recurrence of deep vein thrombosis of the lower limbs, which was present in 40% of cases with inpatient management in the cardiology department. Our patients had all undergone heparin treatment according to the indications in force, but because of its better benefit / risk contribution the LMWH administered rate exceeded that of the UFH (70% against only 30% UFH). The activated partial thromboplastin time (APTT) value is either insufficiently prolonged for 25% of patients with UFH, or inconclusive during LMWH treatment because TCA is the almost exclusive reflection of anti-IIa activity (antithrombin). ). It is for this reason that biological monitoring by measurement of anti-Xa activity is necessary and justified to ensure effective anticoagulation in targeted therapeutic areas without failing to signal the occurrence of induced thrombocytopenia. by heparin or overdose.

PDF Download